AKR1D1 Gene as Potential Drug Target/biomarker for Various Diseases

Target Name: AKR1D1

NCBI ID: G6718

AKR1D1

AKR1D1 Gene as Potential Drug Target/biomarker for Various Diseases

AKR1D1 (also known as cortisone delta 4-5beta-reductase) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, autoimmune disorders, and obesity. The protein encoded by the AKR1D1 gene is involved in the production of cortisol, a hormone that is well-known for its anti-inflammatory and immunosuppressive effects.

Cortisol is a key mediator of many physiological processes in the body, including the regulation of inflammation, stress responses, and glucose metabolism. It is produced by the adrenal glands in response to the presence of stress or other stimuli, and it helps to maintain homeostasis in the body. However, abnormally high levels of cortisol can have negative effects on the body, including increased inflammation, obesity, and an increased risk of certain diseases.

The AKR1D1 gene is located on chromosome 17 and encodes a protein that is composed of 1,112 amino acids. The protein has a molecular weight of 18.9 kDa and a pre-protein cleavage site located at amino acid residue 241. The protein is expressed in many different tissues and cells in the body, including the adrenal glands, fat cells, and immune cells.

Several studies have identified potential drug targets or biomarkers for AKR1D1. One of the most promising targets is the putative target RNA (siRNA), which is a natural RNA molecule that can be used to knockdown (reduce the amount of) the expression of a specific gene. Researchers have generated RNAi screening data for the AKR1D1 gene and have identified several potential siRNA candidates. These candidates have been shown to reduce the expression of the AKR1D1 gene in a variety of cell types, including human primary cultures and mouse models of disease.

Another potential drug target for AKR1D1 is the nuclear factor of activated T cells (NFAT), which is a transcription factor that regulates the expression of many different genes in the body. Researchers have identified a potential interaction between the AKR1D1 gene and NFAT, and have shown that NFAT can be used to increase the expression of the AKR1D1 gene in T cells. This increase in gene expression may contribute to the immunosuppressive effects of cortisol, and could make AKR1D1 a potential target for therapies aimed at reducing inflammation or promoting weight loss.

In addition to its potential as a drug target or biomarker, AKR1D1 has also been identified as a potential biomarker for a number of diseases, including cancer and obesity. Researchers have shown that AKR1D1 gene expression is significantly altered in a variety of tissues and diseases, including cancer, obesity, and autoimmune disorders. For example, studies have shown that the AKR1D1 gene is downregulated in human cancer tissues and that overexpression of the gene has been shown to promote the growth and survival of cancer cells.

In conclusion, the AKR1D1 gene has been identified as a potential drug target or biomarker for a variety of diseases, including cancer and obesity. The protein encoded by the AKR1D1 gene is involved in the production of cortisol, a hormone that has negative effects on the body if abnormally high. The AKR1D1 gene has also been shown to be involved in the regulation of many different genes in the body, and has been identified as a potential target for a variety of therapies aimed at reducing inflammation or promoting weight loss. Further research is needed to fully understand the role of the AKR1D1 gene in these processes and to develop effective therapies.

Protein Name: Aldo-keto Reductase Family 1 Member D1

Functions: Catalyzes the stereospecific NADPH-dependent reduction of the C4-C5 double bond of bile acid intermediates and steroid hormones carrying a delta(4)-3-one structure to yield an A/B cis-ring junction. This cis-configuration is crucial for bile acid biosynthesis and plays important roles in steroid metabolism. Capable of reducing a broad range of delta-(4)-3-ketosteroids from C18 (such as, 17beta-hydroxyestr-4-en-3-one) to C27 (such as, 7alpha-hydroxycholest-4-en-3-one)

The "AKR1D1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKR1D1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets